PTO/SB/08a (08-03)

Name of Patentee or Applicant Where Relevant Passages or

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pakenyork Reduction According 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Cite

Examiner

Substitute for form 14450FTO				Complete if Known		
				Application Number	09/937,375	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			LOSURE	Filing Date	September 24, 2001	
			PLICANT	First Named Inventor	Ikunoshin KATO	
				Group Art Unit		
(use as many sheets as necessary)			ecessary)	Examiner Name		
Sheet	1	of	1	Attorney Docket Number	KATO18	1

U.S. PATENT DOCUMENTS						
Examiner nitials*	Cite No.1	Document Number Number-Kind Code ^{2 (d known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS

Publication Date

Foreign Patent Number

Country Code³ Number⁴ Kind Code³ (if known)

	工		 				
					<u> </u>		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country with published							
A	AP CONNEALLY E. EAVES CJ, HUMPHRIES RK, "Efficient retroviral-mediated gene transfer to human cord blostem cells with in vivo repopulating potential" Blood, vol. 91, No. 9, May 1, 1998; pp 3487-3493						
	AQ	KIEM HP et al, "Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment GH296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor." Blood, September 15, 1998; Vol. 92 No. 6, pp.1878-1886					
	AR	MASON CA et al "Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectin-dependent neointimal formation" Nat. Med. vol.5, No.2, February 1999; pp. 176-182					
V	AS	MORITZ T et al "Firbronectin improves vectors: evidence of direct viral binding 88, No.3: 855-862					

Examiner Signature	Date Considered	11-28-04

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional), ² See Kind Codes of USPTO Patent Documents at www.uspto.gov.or.MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁹ Applicant is to place a check mark here if English language Translation is attached.